ENDONOVO THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.00263 USD | +9.58% |
|
0.00% | -70.11% |
| 2023 | Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
| 2023 | Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval | CI |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 17.44 | 7.483 | 1.905 | 0.4932 | 1.123 | 3.498 |
| Enterprise Value (EV) 1 | 22.71 | 14.97 | 10.56 | 7.114 | 8.219 | 10.65 |
| P/E ratio | -1.3 x | -1.03 x | -0.08 x | -0.62 x | -0.3 x | -0.14 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 89,877,569 x | 6,141,406 x | 2,974,565 x | 15,366,965 x | 25,842,274 x |
| EV / Revenue | - | 179,770,210 x | 34,051,376 x | 42,906,886 x | 112,421,804 x | 78,689,579 x |
| EV / EBITDA | -4.95 x | -4.27 x | -3.34 x | -3.15 x | -5.21 x | -4.07 x |
| EV / FCF | -6.18 x | -7.34 x | 2.52 x | -1.09 x | -11.1 x | 0.71 x |
| FCF Yield | -16.2% | -13.6% | 39.7% | -91.9% | -9% | 140% |
| Price to Book | -1.92 x | -0.69 x | -0.11 x | -0.03 x | -0.07 x | -0.12 x |
| Nbr of stocks (in thousands) | 301 | 411 | 1,003 | 24,536 | 72,013 | 194,327 |
| Reference price 2 | 58.00 | 18.20 | 1.900 | 0.0201 | 0.0156 | 0.0180 |
| Announcement Date | 4/6/18 | 4/15/19 | 5/4/20 | 4/13/21 | 4/14/22 | 4/17/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales | - | 0.0833 | 0.3102 | 0.1658 | 0.0731 | 0.1354 |
| EBITDA 1 | -4.589 | -3.509 | -3.159 | -2.261 | -1.578 | -2.617 |
| EBIT 1 | -4.604 | -4.159 | -3.809 | -2.912 | -2.227 | -3.264 |
| Operating Margin | - | -4,995.33% | -1,228.08% | -1,756.49% | -3,045.68% | -2,411.69% |
| Earnings before Tax (EBT) 1 | -10.81 | -6.436 | -17.31 | -0.3956 | -3.105 | -18.47 |
| Net income 1 | -10.81 | -6.436 | -17.31 | -0.3956 | -3.105 | -18.47 |
| Net margin | - | -7,729.53% | -5,582.37% | -238.6% | -4,247.17% | -13,649.17% |
| EPS 2 | -44.65 | -17.76 | -24.83 | -0.0324 | -0.0519 | -0.1327 |
| Free Cash Flow 1 | -3.675 | -2.039 | 4.189 | -6.534 | -0.7395 | 14.95 |
| FCF margin | - | -2,448.6% | 1,350.52% | -3,941.04% | -1,011.54% | 11,044.55% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/6/18 | 4/15/19 | 5/4/20 | 4/13/21 | 4/14/22 | 4/17/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 5.26 | 7.48 | 8.66 | 6.62 | 7.1 | 7.15 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -1.147 x | -2.133 x | -2.741 x | -2.928 x | -4.496 x | -2.733 x |
| Free Cash Flow 1 | -3.68 | -2.04 | 4.19 | -6.53 | -0.74 | 14.9 |
| ROE (net income / shareholders' equity) | 119% | 61.5% | 109% | 2.27% | 20.6% | 77.1% |
| ROA (Net income/ Total Assets) | -117% | -58.7% | -63.3% | -61.9% | -60.3% | -124% |
| Assets 1 | 9.262 | 10.96 | 27.34 | 0.6392 | 5.148 | 14.89 |
| Book Value Per Share 2 | -30.10 | -26.40 | -17.20 | -0.5900 | -0.2100 | -0.1500 |
| Cash Flow per Share 2 | 0.2800 | 0.8800 | 0.0200 | 0 | 0 | - |
| Capex | - | 0.01 | 0 | - | - | - |
| Capex / Sales | - | 10.77% | 0.84% | - | - | - |
| Announcement Date | 4/6/18 | 4/15/19 | 5/4/20 | 4/13/21 | 4/14/22 | 4/17/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -70.11% | 919K | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ENDV Stock
- Financials Endonovo Therapeutics, Inc.
